Ondine Biomedical Inc. OBIMF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.08M | 2.00M | 1.90M | 1.74M | 1.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.08M | 2.00M | 1.90M | 1.74M | 1.58M |
| Cost of Revenue | 804.30K | 776.20K | 742.00K | 641.00K | 540.80K |
| Gross Profit | 1.28M | 1.22M | 1.16M | 1.10M | 1.04M |
| SG&A Expenses | 7.16M | 7.14M | 7.03M | 7.50M | 8.01M |
| Depreciation & Amortization | 356.10K | 367.00K | 373.30K | 381.10K | 390.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.22M | 24.92M | 23.38M | 21.11M | 18.87M |
| Operating Income | -24.14M | -22.92M | -21.48M | -19.37M | -17.29M |
| Income Before Tax | -23.97M | -22.67M | -21.15M | -19.12M | -17.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.97 | -22.67 | -21.15 | -19.12 | -17.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.97M | -22.67M | -21.15M | -19.12M | -17.12M |
| EBIT | -24.14M | -22.92M | -21.48M | -19.37M | -17.29M |
| EBITDA | -23.93M | -22.71M | -21.27M | -19.17M | -17.12M |
| EPS Basic | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 2.05B | 1.96B | 1.86B | 1.68B | 1.49B |
| Average Diluted Shares Outstanding | 2.05B | 1.96B | 1.86B | 1.68B | 1.49B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |